105 related articles for article (PubMed ID: 10529885)
1. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Deshpande LM; Diekema DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):81-8. PubMed ID: 10529885
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
[TBL] [Abstract][Full Text] [Related]
3. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Ednie LM; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 1998 May; 42(5):1274-7. PubMed ID: 9593166
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
8. Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
Clark CL; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2295-8. PubMed ID: 10471582
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
10. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
Ford AS; Baltch AL; Smith RP; Ritz W
J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
[TBL] [Abstract][Full Text] [Related]
11. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
12. Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.
Cohen MA; Huband MD; Yoder SL; Gage JW; Roland GE
J Antimicrob Chemother; 1998 Jun; 41(6):605-14. PubMed ID: 9687098
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T
Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
[TBL] [Abstract][Full Text] [Related]
14. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
[TBL] [Abstract][Full Text] [Related]
15. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
[TBL] [Abstract][Full Text] [Related]
16. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
Shonekan D; Handwerger S; Mildvan D
J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
